MedTrace Logo

NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure

NCT04342104 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-08-30

No results posted yet for this study

Summary

Evaluate HACOR socre utility and efficacy in predicting NIV and/or CPAP failure in patients with COVID-19 associated respiratory failure.

Propose adaptations to HACOR score based on the "state of art" of COVID-19

Conditions

Interventions

OTHER

Monitoring for aggravation

Monitor patients on CPAP or NIV and analyzing possible variables that may predict failure, namely: * lymphopenia * thrombocytopenia * CRP * ferritin * LDH * troponin I * NT-ProBNP * Liver enzymes * D-dimers * radiologic aggravation " 1 day and 1 week after starting NIV or CPAP

OTHER

Evaluate HACOR score effectivity in this patients

Apply the HACOR score after starting NIV and CPAP and later verify if it was effective in predicting NIV/CPAP failure

Sponsors & Collaborators

  • Hospital General Universitario Morales Meseguer

    lead OTHER

Principal Investigators

  • Miguel Guia · Hospital General Universitario Morales Meseguer

  • Antonio Esquinas · Hospital General Universitario Morales Meseguer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2020-11-30
Completion
2021-11-15

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04342104 on ClinicalTrials.gov